Business & Finance In Brief
This article was originally published in The Tan Sheet
Executive Summary
Merck CEO Frazier touts the value of OTCs for extending the drug life cycle; Abbott Nutrition plans nearly 40 product launches across 30 countries by 2017; Herbalife growth reflects global weight management and wellness concerns.
You may also be interested in...
In Brief
Lawmakers push energy drink investigation; Innophos buys Triarco; BASF sweetens Pronova bid; meclizine mix-up spurs iron supplement recall; Abbott Nutrition margin growth on track; Neptune’s struggles continue; Vitamin Shoppe reaches Canada; more news In Brief.
Abbott Nutritionals Rise In Stature With Departure Of Branded Rx
Abbott Laboratories’ nutrition business – one of four divisions in the remaining diversified medical products firm – gains importance with the firm’s plan to spin off its research-based branded pharmaceuticals business.
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.